Global Premature Ejaculation Therapeutics Market Overview
Premature Ejaculation Therapeutics Market was valued at US$ 2.8 Billion in 2024 and is projected to grow at a CAGR of 9% to reach US$ 26.6 Billion by 2034.
A premature ejaculation is a form of sexual dysfunction in which a man ejaculates sooner than expected by the partner during sexual intercourse. Premature ejaculation is caused due to both psychological and medical factors, including stress and diabetes. The premature ejaculation therapeutics report classifies the syndrome in two types such as primary and secondary. Primary premature ejaculation occurs from the time a male becomes sexually active. Secondary premature ejaculation, also known as acquired premature ejaculation, develops after a man has had previous sexual experiences without ejaculatory problems.
Drivers and Restraints:
Increasing incidences of emotional and mental stress and other male sexual disorders, especially erectile dysfunction (ED) is giving proper treatment choices for a range of wide diseases which is the major driving factor for the growth of the global premature ejaculation therapeutics market. PE is the most prevalent sexual disorder among men across the globe. Additionally, in recent years the progress in medical research has increased the knowledge about several diseases to an in-depth level, thereby disclosing new target sites for drug treatment in the global market. There are quite a few numbers of the drug under investigation for treating PE in the worldwide market. With the presence of a single approved oral premature ejaculation drug, the market regionally and globally is dominated by off-label drugs, generic versions of patent expired drugs and OTC formulations. Nevertheless, the growing demand for various off-label and generic therapeutics will create an opportunity for the growth of the target market.
Segmentation:
The premature ejaculation therapeutics market is segmented based on drug class, route of administration and region.
Based on drug class, the premature ejaculation therapeutics market is segmented into the SSRIs, PDE5 inhibitors, and anesthetic agents. Based on the route of administrations, the target market is segmented into oral therapeutics and topical therapeutics.
Based on the region the premature ejaculation therapeutics market is segmented North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is expected to account for significant revenue share for the targeted market due to the rising lifestyle-related stress, the rise in chronic conditions, which can lead to the incidence of PE. Whereas, the high disease prevalence population, improvement in healthcare spending, increase in PE awareness, increase in uptake of PE drugs are fueling the demand across the Asia Pacific region in the global premature ejaculation therapeutics market.
Key Players:
The key players in the premature ejaculation therapeutic market involve Absorption Pharmaceuticals, innovus Pharmaceuticals, Pfizer, Plethora Solutions Holdings, Bayer, Eli Lilly and Company, GlaxoSmithKline, Recordati, Royalty Pharma, and The Menarini Group. The global premature ejaculation therapeutics market is fairly fragmented due to the presence of pharma companies and generic manufacturers. The top vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents to attract the maximum number of consumers in the global market.
Detailed Segmentation:
Premature Ejaculation Therapeutics Market, By Drug Class:
- SSRIs
- PDE5 Inhibitors
- Anesthetic Agents
- Others
Premature Ejaculation Therapeutics Market, By Route of Administration:
- Oral Therapeutics
- Topical Therapeutics
Premature Ejaculation Therapeutics Market, By Region:
- North America
- Middle East & Africa
- Middle East & Africa Premature Ejaculation Therapeutics Market, By Drug Type
- Middle East & Africa Premature Ejaculation Therapeutics Market, By Route of Administration
- Middle East & Africa Premature Ejaculation Therapeutics Market, By Country
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Latin America Premature Ejaculation Therapeutics Market, By Drug Type
- Latin America Premature Ejaculation Therapeutics Market, By Route of Administration
- Latin America Premature Ejaculation Therapeutics Market, By Country
- Brazil
- Argentina
- Rest of Latin America
- Asia Pacific
- Asia Pacific Premature Ejaculation Therapeutics Market, By Drug Type
- Asia Pacific Premature Ejaculation Therapeutics Market, By Route of Administration
- Asia Pacific Premature Ejaculation Therapeutics Market, By Country
- China
- India
- Japan
- Australia
- Rest of Asia Pacific
- Europe
- Europe Premature Ejaculation Therapeutics Market, By Drug Class
- Europe Premature Ejaculation Therapeutics Market, By Route of Administration
- Europe Premature Ejaculation Therapeutics Market, By Country
- Spain
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- North America Premature Ejaculation Therapeutics Market, By Drug Class
- North America Premature Ejaculation Therapeutics Market, By Route of Administration
- North America Premature Ejaculation Therapeutics Market, By Country
- U.S.
- Canada
- Middle East & Africa
Company Profile:
- Absorption Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Innovus Pharmaceuticals
- Pfizer
- Plethora Solutions Holdings
- Bayer
- Elli Lily and Company
- Glaxosmithkline
- Record
- Royalty Pharma
- The Menarini Group
“*” marked represent similar segmentation in other categories in the respective section
Key Issues Addressed
- What is the total revenue potential of the global premature ejaculation therapeutics market? How that market is expected to grow during the study period?
- What are some of the major growth opportunities in the premature ejaculation therapeutics market?
- Which companies are the major players in the premature ejaculation therapeutics market?
FAQs
The premature ejaculation therapeutics market is segmented based on drug class, route of administration and region.
the development of novel therapeutic approaches, the focus on combination therapies, and advancements in personalized medicine for premature ejaculation, presenting significant opportunities in the global Premature Ejaculation Therapeutics Market.
increasing prevalence of premature ejaculation, the growing awareness of sexual health, advancements in pharmacotherapy for sexual disorders, and the demand for effective and well-tolerated premature ejaculation treatments.
North America and Europe are expected to dominate the Premature Ejaculation Therapeutics Market, driven by a high prevalence of sexual disorders, advanced healthcare infrastructure, and significant research and development activities in these regions.
The key players in the global premature ejaculation therapeutic market involve Absorption Pharmaceuticals, innovus Pharmaceuticals, Pfizer, Plethora Solutions Holdings, Bayer, Eli Lilly and Company, GlaxoSmithKline, Recordati, Royalty Pharma, and The Menarini Group.